<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-659
Date of Submission: 2025-05-29

This report was submitted by a Other Healthcare Professional from Sanders LLC Medical Center concerning patient ANON-PX-7462. The subject is a 28-year-old other with a significant medical history including asthma, atrial fibrillation, type 2 diabetes, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Intravenous route at a dosage of 108mg, initiated on 2025-04-21 for Neuropathic pain and discontinued on 2025-05-25.

On approximately 2025-05-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Headache, Diarrhea. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Back small foot drug. Information project future place. Use little event those hair.</data>
report_id: ADR-2025-659
report_date: '2025-05-29'
patient_details:
  patient_id: ANON-PX-7462
  gender: Other
  relevant_history:
  - asthma
  - atrial fibrillation
  - type 2 diabetes
  - chronic kidney disease
  age_at_reaction: 28
suspected_drugs:
- drug_name: Gabapentin
  dosage: 108mg
  route_of_administration: Intravenous
  start_date: '2025-04-21'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2025-05-25'
adverse_reactions:
- symptom_name: Dizziness
  onset_date: '2025-05-25'
  severity: Severe
  outcome: Recovered
  intervention_required: false
- symptom_name: Headache
  onset_date: '2025-05-25'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
- symptom_name: Diarrhea
  onset_date: '2025-05-25'
  severity: Moderate
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Negative dechallenge
  naranjo_score: 7
reporting_facility: Sanders LLC Medical Center
reporter_type: Other Healthcare Professional
notes: Back small foot drug. Information project future place. Use little event those
  hair.
